Our data demonstrate that myocyte PKD2 channels are upregulated during hypertension and that PKD2 targeting reduces vasoconstriction, blood pressure and arterial remodeling during hypertension, eliciting multi-modal benefits. Here, PKD2 is linked to Hypertension.